Orphelia Pharma Portfolio
Rare pediatric neurology and oncology diseases
Not Specified (Acquired Pipeline)Active
Key Facts
Indication
Rare pediatric neurology and oncology diseases
Phase
Not Specified (Acquired Pipeline)
Status
Active
Company
About Orphalan
Orphalan SA is a global, commercial-stage orphan drug company focused on rare diseases, with a primary anchor in Wilson disease. The company has successfully developed and gained marketing authorization for its lead product, trientine tetrahydrochloride (Cuprior®/Cuvrior®), which is now available in over 30 countries. Through recent strategic acquisitions, such as Orphelia Pharma, and expansion into key markets like China and the US, Orphalan is building a broader rare disease portfolio, particularly in pediatric neurology and oncology. The company employs over 100 people and maintains a dedicated international team across more than 20 countries.
View full company profile